Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells
详细信息 查看全文
- 作者：Isao Kobayashia ; b ; 1 ; Fumiyuki Takahashia ; b ; 1 ; fumiyuki@dol.hi-ho.ne.jp" class="auth_mail" title="E-mail the corresponding author ; Fariz Nurwidyaa ; b ; Takeshi Narac ; Muneaki Hashimotoc ; Akiko Murakamia ; b ; Shigehiro Yagishitaa ; b ; Ken Tajimaa ; b ; Moulid Hidayata ; b ; Naoko Shimadaa ; b ; d ; Kentaro Suinaa ; b ; Yasuko Yoshiokaa ; b ; Shinichi Sasakia ; b ; Mariko Moriyamae ; Hiroyuki Moriyamae ; Kazuhisa Takahashia ; b ; d
- 关键词：Oct4 ; Gefitinib resistance ; Cancer stem cell ; NSCLC
- 刊名：Biochemical and Biophysical Research Communications
- 出版年：2016
- 出版时间：22 April 2016
- 年：2016
- 卷：473
- 期：1
- 页码：125-132
- 全文大小：1126 K
文摘
- •
Oct4 is highly expressed in gefitinib-resistant tumors of EGFR-mutant NSCLC in vivo.
- •
Oct4 induces gefitinib resistance in vitro and in vivo.
- •
Oct4 increases CD133-positive gefitinib-resistant persisters.
- •
Oct4 promotes properties of cancer stem cells under the gefitinib treatment.
- •
Oct4 is highly expressed in tumors of patients with acquired resistance to gefitinib.